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Abstract: Genetic variations and gender contribute significantly to the large interpatient varia-
tions in opioid-related serious adverse effects and differences in pain relief with other analgesics. 
Opioids are the most commonly used analgesics to relieve moderate-to-severe postoperative 
pain. Narrow therapeutic index and unexplained large interpatient variations in opioid-related 
serious adverse effects and analgesia negatively affect optimal perioperative outcomes. In surgi-
cal, experimental, chronic, and neuropathic pain models, females have been reported to have 
more pain than males. This review focuses on literature evidence of differences in pain relief 
due to multiple genetic variations and gender of the patient.
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Introduction
Individual variation in pain perception and response to analgesics has been a subject 
of interest for quite some time now. Genetic factors and sex of the patient are associ-
ated with differences in analgesia. For instance, the MC1R gene, which is associated 
with fair skin and red hair, has been found to play a role in sexual dimorphism of 
kappa-opioid analgesia. Red-haired women, with two variants of the MC1R allele, 
showed significantly greater analgesia in response to pentazocine, compared to red-
haired men.1 This is an example of the role played by chromosomal sex in dissimilar 
responses to analgesic therapy, secondary to a specific genotype. There have been case 
reports of life-threatening respiratory depression in response to tramadol,2,3 codeine,4 
and so on, in extensive metabolizers (EMs) of the prodrugs to their respective active 
forms. There are a number of other factors such as age, body composition, hormonal 
milieu, comorbid conditions, co-existing pharmacotherapy, past pain experiences, and 
environmental and psychosocial factors that play a role in the individual variation in 
the experience of pain and analgesia. Curiosity in this individual variation began ever 
since the period of Pythagoras, who noticed that some experienced fatal reactions 
on ingesting fava beans and others did not.5 Today, in an era of epigenetic therapies, 
understanding the genetic and gender differences in drug metabolism and drug response 
holds extreme significance and it has been facilitated by the successful completion of 
the human genome project in 2003.
This review aims to shed light on the gender differences and pharmacogenetics 
relevant to pain management. Pain is a subjective experience, which includes physical 
as well as emotional components, and is difficult to measure objectively. Each person 
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is unique in perception and response to pain and so is each 
individual’s response to analgesic therapy. The WHO pain 
ladder, which is a simple yet effective algorithm to manage 
pain, is nonetheless, an over-generalized management guide-
line when individual differences are considered. Understand-
ing these differences is the first step toward individualized 
medicine or tailoring therapy to each individual, or in other 
words, a step toward an “ideal analgesic therapy”.
Gender differences in pain perception
In order to understand the gender difference in response to 
pain relief, understanding the gender difference in pain per-
ception is the first essential step. It has been now understood 
that this difference is due to a multitude of other factors than 
just the chromosomal sex. Hence, it is more appropriate to 
address it as “the gender difference”, as it encompasses the 
psychological and social aspects of sex as well. Phenotypic 
expression of various alleles has more relevance in individual 
differences in pain perception and analgesic response, rather 
than just the presence of a distinct genotype, and this expres-
sion, in turn, is influenced by a number of other internal and 
environmental factors.
There are a number of studies that examine the gender 
differences in pain perception. Though the results are mixed, a 
majority of them point in the direction of increased sensitivity 
to pain in females.6 Females are at an increased risk of many 
chronic pain conditions compared to males. The population 
prevalence of several pain conditions such as migraine, ten-
sion headache, irritable bowel syndrome, and fibromyalgia 
is higher in females.6–9
Females also show a higher incidence of acute postop-
erative pain.6 Females are also reported to have an increased 
sensitivity in a number of experimental pain models. This 
includes pain induced by electrical, thermal, mechanical, 
chemical stimuli, or more advanced, clinically relevant 
pain models such as the temporal summation of pain and 
conditioned pain modulation (CPM).7 Temporal summation 
measures pain facilitation in response to repeated stimuli 
over a period of time. CPM measures a decrease in pain 
perception in response to a “conditioning pain stimulus”. It 
is based on “pain inhibits pain” model and is used to assess 
endogenous antinociception. Responses are measured in 
terms of pain intensity scales such as the visual analog 
scale, self-reported unpleasantness rating, and in terms 
of threshold and tolerance. Threshold measures the time 
or intensity of stimulus at which the subject first reports 
pain perception. Tolerance is the maximum amount of pain 
stimulus the subject is able to withstand. In general, females 
display a lower pain threshold and tolerance to painful 
stimuli compared to males. Women show a greater temporal 
summation of pain (pain facilitation), whereas men show 
better pain modulation (pain inhibition).6–9 Pain modula-
tion through diffuse noxious inhibitory control (DNIC) 
has been found more efficient in men than in women.10 In a 
recent review by Hermans et al, nine of the 15 studies that 
compared CPM between males and females did not find any 
difference between the genders. The remaining six studies 
found that males demonstrated better CPM compared to 
females.11 Though evidence of gender difference in CPM 
is not compelling, those studies that show a difference 
consistently point toward greater CPM in males.
Causes of gender differences in pain 
perception
Sex hormones and neural correlates
Sex hormones have been known to play a significant role in 
gender difference in pain perception and analgesia.12 Testos-
terone has been found to decrease pain sensitivity, and a low 
testosterone state has been demonstrated in many chronic 
pain conditions,13 but the effects of estrogen and progesterone 
on pain are more complicated, with both pro- and antinoci-
ceptive properties.14,15 Use of exogenous sex hormones has 
also been related to an increased risk of chronic pain condi-
tions.16 Considering the role of sex hormones in nocicep-
tion, intragroup variation in pain perception in females and 
variations in the same individual at various stages of sexual 
development and cyclical variation with the menstrual cycle 
hold clinical significance, though the literature evidence is 
inconsistent.17–20 For instance, many studies suggested that 
females in postovulatory luteal phase show increased pain 
sensitivity compared to follicular phase.21 Pain symptoms in 
chronic pain conditions seem to be most severe around men-
struation, associated with the falling levels of estrogen.17,22 
Other studies have shown an association between high levels 
of female reproductive hormones and pain conditions.16,22 
To add to this controversy, there is a growing body of recent 
literature, suggesting a lack of variability in pain response 
across the menstrual cycle.22,23 More studies are required to 
gain further insight.
Age of the individual plays an important role in pain 
sensitivity and analgesic response due to variation in sex 
hormone levels and differences in body composition and 
metabolic ability. Many chronic pain conditions show no 
difference in prevalence, between genders, and before 
puberty.12 Females show an increased prevalence of 
these conditions around puberty.24 Gender difference in 
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cortical pain processing has also been demonstrated.25,26 
 Neuroimaging has demonstrated reduced pain-related 
activation of CNS antinociceptive pathways in females with 
low testosterone levels.27 Animal studies also show a sexual 
dimorphism in the anatomy and function of the CNS pain 
modulatory system.28 Midbrain periaqueductal gray (PAG) 
matter and its descending projections to the rostral ventro-
medial medulla (RVM) and spinal cord form an important 
descending antinociceptive pathway.28–31 Pain stimulates 
PAG, resulting in a release of endogenous opioids. Studies 
in rats showed no qualitative sex difference in the PAG–
RVM system, but quantitatively, female rats had a greater 
number of neurons compared to the males.28,32,33 On the 
contrary, functional studies have shown significantly lower 
activation of PAG–RVM neurons in response to persistent 
inflammatory pain in female rats compared to male rats. 
Despite this difference, both male and female rats exhibited 
similar hyperalgesia after chemically induced inflammatory 
pain. This suggests the existence of alternative, sex-specific 
pain-modulating pathways.28
Sexual dimorphism has also been observed in mu-opioid 
receptors (MOR). Males have higher levels of MOR expres-
sion and better opioid binding in the rostrocaudal axis of 
PAG.28 This may have an association with increased andro-
gen receptor (AR) expression in PAG neurons. Estradiol, in 
contrast, has been known to cause MOR internalization and 
to attenuate neuronal hyperpolarization secondary to MOR 
activation.34–36 Sex difference has also been noticed in the 
MOR second messenger-signaling cascade.37,38
Sex hormones also influence spinal cord pain modula-
tion.39,40 When estrogen levels are high, spinal antinoci-
ception was robust in female rats and was comparable to 
males.28 This is because estrogen has been found to facilitate 
heterodimerization of kappa-opioid receptors (KOR) and 
MOR (KOR/MOR heterodimers), and the KOR binding of 
opioids plays a significant role in the spinal antinociception 
in females.41,42
Hormonal influence in peripheral pain processing has 
also been studied, especially in inflammatory pain.43,44 
Inflammation-induced proinflammatory peptides’ release 
has been found to vary with the phase of the menstrual 
cycle.45
Dimorphism in a number of other pain neurotransmitters 
and their receptors has also been studied. Some examples 
include NMDA receptors,46 orphanin FQ/nociception,47 
protein kinases,48 toll-like receptor 4 (TLR4),49 adenosine 
receptors,50 cannabimimetic lipids,51 cytokine expression,52 
monoamine receptors,53 neuregulin 1,54 and neurosteroids.55 
All the above-discussed gender difference in nociceptive and 
pain-modulating pathways are significant, since they may 
also play an important role in sexual dimorphism of opioid 
analgesia, which is discussed later.
Comorbid conditions
Females with chronic pain conditions show increased pain 
facilitation such as temporal summation, and this phenom-
enon is not seen in males. Increased prevalence of depression 
and anxiety in females compared to males is also a likely 
cause of gender difference in pain perception.12
Social factors
Social factors besides genetics and gender differences can 
influence pain perception significantly. Gender role expec-
tations, stereotypes, and cultural differences in pain-related 
beliefs play an important role in gender difference in pain 
across various cultural and ethnic backgrounds.56,57 Past life 
pain experiences and environmental stress have also been 
shown to influence pain perception.58 Childhood abuse has 
been found to be associated with an increased incidence of 
chronic pain in adulthood.59
Psychological factors
Behavioral modifications, pain coping strategies, represent 
the first response in handling pain. Females are known to 
use a variety of coping mechanisms such as seeking social 
support, emotion-focused techniques, attention focus, cog-
nitive re-interpretation, and positive self-statement.60,61 Men 
more frequently engage in problem-focused techniques and 
behavioral distraction to handle pain.6,60,61
Women are known to catastrophize more than men, and 
this involves magnification and self-rumination of pain-
related information.62,63 Catastrophizing is associated with 
chronic and persistent pain. Men show higher degrees of 
self-efficacy, which refers to the belief that one can success-
fully perform a behavior to achieve a goal.64,65
Incidences of depression and anxiety differ among males 
and females, and these psychological factors increase the 
risk for pain perception and transition from acute pain to 
chronic pain.
Gender and analgesic response
The gender differences in drug response can either be phar-
macokinetic or pharmacodynamic differences. Body compo-
sition and metabolism differ between genders. Sex hormones 
also influence protein binding and metabolism of various 
drugs, introducing a pharmacokinetic  dimorphism.66,67 
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Examples of pharmacodynamic differences include MOR 
dimorphism and sex hormonal influences on MOR second 
messenger activation.28 The existence of alternate, sex-
specific, pain modulating pathways also influences analgesic 
response.28
It is observed that women are more likely to be pre-
scribed analgesic medications especially nonsteroidal 
anti-inflammatory agents (NSAIDs).68,69 Women also use 
more over the counter analgesics compared to men.70 This 
may reflect a higher prevalence of many inflammatory and 
chronic pain conditions among women compared to men. 
Among NSAIDs, men have demonstrated better pain control 
with ibuprofen,71 while women reported better analgesia 
with ketorolac,72 but the abovementioned studies measured 
response to experimental pain. In an animal study, cyclo-
oxygenase (COX) knockout female mice exhibited reduced 
joint destruction compared to COX knockout male mice.73 
Thus, a gender difference in analgesic and anti-inflammatory 
properties of NSAIDs is possible.
Studies on gender differences in opioids have yielded 
mixed results. Postoperative morphine consumption has been 
found to be lower in women compared to men.56 Most of these 
studies examine the dose of opioid consumed, which may also 
be influenced by the gender-specific differences in the side 
effect profile of the opioid, rather than the analgesic efficacy 
itself. Some studies have measured the gender difference in 
analgesic efficacy of morphine. Some of them reported better 
morphine analgesia in women, some reported in men, and 
others reported no gender difference.12 There are some animal 
studies that report a greater degree of morphine analgesia 
in males.28 There are a number of factors contributing to the 
above finding.
The dimorphism of PAG–RVM pain modulation pathway 
has been already discussed. Morphine-induced activation 
of PAG–RVM neurons was significantly higher in males.28 
Effects of sex hormones on MOR have also been discussed. 
Morphine, in addition to its action on MOR, has also been 
found to act on TLR4 of glial cells, inducing a neuroinflam-
matory response, which directly opposes morphine analgesia. 
More active innate immunity and a greater degree of TLR4 
expression in females may be another reason for the gender 
difference in morphine analgesia.49
Women are shown to experience better analgesia in 
response to mixed action opioids such as butorphanol, 
nalbuphine, and pentazocine.56 One significant example is 
the gene–sex interaction involving the melanocortin recep-
tor (MC1R) gene.1 Red-haired, fair-skinned women with 
two allelic variants of the MC1R gene demonstrated better 
analgesia from pentazocine compared to red-haired men and 
women who did not have the allelic variants.
Females also showed an increased incidence of opioid-
related adverse effects such as respiratory depression and 
postoperative nausea and vomiting (PONV) compared to 
males.74 Prepubertal girls have been shown to have a greater 
incidence of PONV and respiratory depression after tonsil-
lectomy at higher morphine doses compared to boys.75 This 
unequal burden of adverse effects can contribute to lower 
opioid consumption in females.
Differences in analgesic response to antiepileptic and 
antidepressant medications are not widely studied. There 
is one study that reported no gender difference in analgesic 
efficacy of paroxetine.76 Knowledge about gender difference 
in response to regional analgesic modalities is also limited. 
From the above discussion, it becomes clear that there is 
no strong evidence that would support a gender-specific 
analgesic intervention in most clinical situations, at present.
Genetic differences in pain and analgesia
Each person is unique in the way he/she responds to pain; 
similarly, response to analgesic therapy also immensely var-
ies with each individual. Race of an individual imposes an 
unequal burden of postoperative pain and adverse effects to 
analgesics. One observational study showed that Caucasian 
children have less postoperative pain and a higher incidence 
of opioid-related adverse effects after tonsillectomy.77 
Another study reported that Asian Americans have a lower 
pain threshold and tolerance to experimental pain compared 
to non-Hispanic Whites.78 In a recent review of the literature 
on racial differences in experimental pain, it was concluded 
that ethnic minorities such as African Americans and Hispan-
ics showed lower tolerance and greater unpleasantness scores 
for suprathreshold pain stimuli compared to non-Hispanic 
Whites. There was no strong evidence of a racial difference 
in pain threshold. The authors concluded that the difference 
in tolerance and pain ratings in the suprathreshold range is 
relevant to clinical pain experience and more research is 
required in exploring the biopsychosocial factors that cause 
this difference.79 These demonstrate the role of genetic 
variation (genetic ancestry) along with psychosocial and 
environmental factors and life experiences in shaping an 
individual’s pain experience.
The same drug at the same dosage may cause therapeutic 
effects in some and adverse drug effects in the others, while 
some others may experience no effect at all. This wide range 
of variability is in part due to genetic variability. The conven-
tional analgesic regime that is based on the type of pain, its 
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intensity, age, and body weight of the person does not take 
into account this genetic variability, thus introducing a huge 
factor of uncertainty. Pharmacogenomics may have a big role 
in the dawn of the era of personalized medicine, tailored to 
meet the individual patient’s profile, thereby ensuring better 
efficacy and absolute safety.
The molecular basis of this variability includes a number 
of genetic variants.80 The most common genetic variant is the 
single-nucleotide polymorphism (SNP), which represents the 
alteration in one single base in the DNA fragments. Dele-
tion or insertion of single or multiple base pairs, continu-
ous repeats of 2–4 bases (variable number tandem repeats 
[VNTR]), repeats of longer DNA fragments (micro- and 
minisatellites), repeats of larger DNA fragments or the whole 
genes (copy number variants [CNV]), and chromosomal 
aberrations constitute the other genetic variants. These vari-
ants, under multiple influences, express themselves resulting 
in the unique phenotype. This is effected via the change in 
structure or function or level of expression of various pro-
teins, including enzymes, transport proteins, receptors, and 
second messenger systems.
Functional pain genomics
Genetic variability in the field of pain includes functional 
pain genomics and pharmacogenomics.80 Functional pain 
genomics explains the individual risk of developing pain, pain 
intensity, intrinsic pain modulation, and individual response 
to pain. Some examples include genetic conditions such as 
congenital insensitivity to pain,81 channelopathy-associated 
insensitivity to pain,82 and primary erythromelalgia.83 There 
are few other single-gene pain disorders. The above condi-
tions are very rare, but understanding the pathophysiology of 
the above conditions may open new targets for analgesic drug 
therapy and for genetic intervention in pain management.84 
For example, black mamba venom has been found to abolish 
pain by its action on acid-sensing ion channels.85 Another 
clinically relevant finding is the existence of polymorphism 
in minor A allele of SCN9A rs6746030 gene, causing altered 
pain threshold, resulting in individuals to experience differ-
ent amounts of pain, in response to standard nociceptive 
stimulus.86 This is important because pain intensity is usually 
a major factor dictating choice and dosage of analgesics.
Individual differences in pain sensitivity and perception 
may be partly explained by differences in nociceptive path-
ways. Catecholamines, such as norepinephrine and dopamine, 
play a vital role in these pathways, and CNS dopamine 
levels are related to the production of endogenous opioids 
that modulate pain. Genetic variability of the COMT gene, 
which codes for catechol-O-methyl transferase (COMT), 
an enzyme that degrades catecholamines in the CNS, has 
been found to play a role in individual pain perception.87,88 
Similarly, a number of other gene polymorphisms are linked 
to individual pain sensitivity. These include genes coding for 
GTP cyclohydrolase 1 (GCH1),89 estrogen receptor (ESR1), 
MOR (OPRM1),90 neurotropin tyrosine kinase receptor type 
1 (NTRK1), nerve growth factor β (NGFb),91 and so on.
Another area involving functional genomics in pain 
perception is the role of psychological factors in pain expe-
rience, especially chronic pain. In a study, the presence of a 
certain polymorphism in the promoter region of the serotonin 
transporter gene 5-HTTLPR has been found to correlate with 
neurotic behavior, high levels of anxiety, self-doubt, and 
negative emotions.92 The abovementioned personality traits 
cause inability to cope with negative emotions associated 
with pain, resulting in catastrophizing.84 Similarly, serotonin 
(5HT) is involved in the modulation of depression. Persons 
with certain alleles of 5HTR1A and 5HTR2A (serotonin 
receptors) are found to show a higher incidence of postopera-
tive depression and pain.93
Pharmacogenomics
Pharmacogenomics is the study of genetic variabilities that 
underlie variations in drug response. These variations may 
be pharmacokinetic or pharmacodynamic differences. In 
general, pharmacokinetic variability is seen at two levels, 
either at the conversion of the prodrug to its active form or 
at the elimination of the active drug. Other areas of pharma-
cokinetic variability include protein binding of the drug and 
the transmembrane transport of the drug, which determine 
the effect site concentration of the drug. Pharmacodynamic 
variations occur at receptor binding, and second messenger 
activation, that occurs after receptor binding.
Pharmacokinetics
The metabolism of drugs occurs in two phases. Phase I 
involves oxidation, reduction, hydrolysis, and so on. Phase 
II involves conjugation of substrates to form water-soluble 
products. Majority of the Phase I enzymes belong to the 
cytochrome P 450 (CYP450) family, which is responsible for 
the metabolism of over 80% of all therapeutic drugs.94 Some 
of the notable subfamilies include CYP2D6 and CYP2C9.
CYP2D6 enzymes metabolize over 20% of all currently 
available drugs and are subject to over 100-fold genetic 
variability in their expression and level of activity.94 There 
are more than 100 CYP2D6 alleles identified that occur in 
varying frequencies in various ethnic groups.80 Based on the 
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allelic combinations and variants, patients can be categorized 
under the following four phenotypic groups: poor metaboliz-
ers (PMs), intermediate metabolizers (IMs), extensive metab-
olisers (EMs), and ultrarapid metabolizers (UMs). Codeine 
is a widely used opioid, which undergoes CYP2D6-mediated 
O-demethylation to form its active drug morphine. Codeine 
itself is a prodrug, with lower affinity and intrinsic activity 
on MOR. PMs produce very low amounts of morphine, while 
UM produce excessive amounts of morphine. Therefore, PMs 
show no or subnormal therapeutic response to codeine, while 
UMs exhibit significant adverse effects including respiratory 
depression, excessive sedation, and vomiting. There are 
many case reports of codeine-induced respiratory depression 
and deaths in UMs, especially in children and in breast-fed 
neonates after maternal codeine administration.4,95–98 This 
has led to the US Food and Drug Administration’s warning 
against the prescription of codeine in nursing mothers94 and 
children undergoing tonsillectomy surgery. The Clinical 
Pharmacogenetics Implementation Consortium (CPIC) has 
published dosing guidelines for codeine and other opioids 
based on CYP2D6 genotype, which will be discussed later.
Tramadol is another CYP2D6 substrate and is trans-
formed into its active metabolite O-desmethyltramadol. 
Though tramadol itself has some analgesic action via its 
action on MOR and nonopioid serotonin, noradrenaline-
mediated CNS antinociceptive pathways, the major analgesic 
action is via O-desmethyltramadol. Hence, the phenotype 
of CYP2D6 plays a major role in an individual’s analgesic 
response to tramadol.99,100 Respiratory depression has been 
reported in UMs after tramadol administration.2
Another example is genetically variable CYP3A system 
involved in the conversion of parecoxib to valdecoxib.80 
Tricyclic antidepressants such as amitriptyline are used 
as co-analgesics especially in chronic pain. They undergo 
activation in the liver, which occurs in the following two 
steps: CYP2D6 hydroxylation and CYP2C19 demethylation. 
CYP2D6 PMs have higher blood concentrations of cyclic 
antidepressants, hence, an increased incidence of side effects 
such as arrhythmia and myelosuppression.101
Uridine diphosphate glucuronosyltransferase (UGT) 
belongs to a group of Phase II enzymes involved in conju-
gation reactions. Morphine is a substrate of UGT2B7 in the 
liver and is conjugated to two metabolites such as morphine 
3 glucuronide (M3G) and morphine 6 glucuronide (M6G).102 
M3G forms 75–85% of the metabolites and is pharmacologi-
cally inactive. M6G is the minor metabolite (5–10%) and is 
a potent analgesic. A number of polymorphisms of the UGT 
enzyme have been identified. Altered response to morphine in 
relation to specific UGT genotypes has been observed in vari-
ous studies.103,104 Similarly, methadone, fentanyl, alfentanil, 
and sufentanil elimination are subject to genetic variability 
in the CYP3A enzyme system.105,106
NSAIDs are widely used nonopioid analgesics, alone or 
as part of a multimodal analgesic regimen. They are metabo-
lized and eliminated by the CYP2C9 enzyme system, which 
has been known to show a wide genetic variability. PMs 
show decreased clearance and increased incidence of NSAID 
toxicity, especially gastrointestinal bleeding.107–110 CYP2C9 
is also involved in warfarin metabolism, allelic variants that 
decrease the clearance of warfarin and increase bleeding risk, 
which is compounded when NSAIDs are prescribed alongside 
warfarin in patients carrying these variants.111
The P-glycoprotein ABCB1/MDR1 transporter is an 
ATP-dependent efflux transporter found in various tissues. 
It greatly affects the plasma and effect site concentrations of 
the substrate drugs. The ABCB1 gene is highly polymorphic. 
Morphine is a P-glycoprotein substrate, which transports 
morphine out across the blood–brain barrier, hence decreases 
CSF concentration of morphine. Hence, genetic variability 
in ABCB1 may be responsible for morphine-induced respi-
ratory depression and the significant variability in analgesic 
response to morphine.112 There is also a study showing pro-
longed respiratory depression after fentanyl administration 
in certain ABCB1/MDR1 genotypes.113,114
Hepatic cellular uptake of morphine is mediated through 
organic cation transporter (OCT1), and efflux of M3G and 
M6G is mediated through ABCC3. Genetic polymorphism 
in OCT1 has also been studied.115
Pharmacodynamics
Drugs interact with their specific receptors and initiate a cas-
cade involving the second messenger system, finally culmi-
nating in the drug effect. The components in this cascade are 
subject to genetic variability resulting in variable responses.
MOR belongs to a family of 7-transmembrane G-protein-
coupled receptors (GPCR). OPRM1 gene coding for MOR 
is highly polymorphic, and there are case reports of OPRM1 
variants with significantly decreased analgesic response to 
opioids and greater postoperative opioid requirements.116,117 
There are many studies on genetic variability of MOR and its 
relation to pain, but the results are inconsistent.118,119
Nonfunctional variants of the MC1R gene, which results 
in red hair and fair skin, are associated with sexual dimor-
phism in kappa-opioid responses. Red-haired women with 
these MC1R variants are known to require a lesser dose of 
drugs such as pentazocine compared to red-haired men.1,120
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NSAIDs act through the inhibition of COX pathways. 
Prostaglandin-endoperoxide synthase (PTGS) 1 and 2 
code for COX 1 and 2, respectively. Genetic variations in 
these enzymes can result in an altered NSAID response.121 
Individuals with an increased expression of PTGS 2 and 
hence COX 2 experience better analgesic response to COX 
2-specific agents such as celecoxib, while lower levels of 
expression of COX 2 result in better analgesic response to 
nonselective NSAIDs.84
COMT degrades neurotransmitters such as epinephrine, 
norepinephrine, and dopamine, which play an integral role 
in CNS pain pathways. Increased dopamine suppresses the 
production of endogenous opioid peptides, which in turn 
upregulates opioid receptor levels and hence altered response 
to opioids. Genetic variability in COMT expression has been 
related to variability in opioid dose requirements.122–124
Local anesthetics are sodium channel inhibitors; hence, 
genetic variations in sodium channels may be expected to 
alter local anesthetic binding and response. This has been 
proven by in vitro studies showing greater resistance to 
lidocaine in certain mutations of the SCN9A gene coding for 
sodium channels.125 This has also been linked to increased 
susceptibility to local anesthetic toxicity.126
Apart from pharmacokinetic and pharmacodynamic 
variabilities in drug responses, genetic variability in immune-
mediated drug hypersensitivity has been studied. Antiepilep-
tics are increasingly used in the management of chronic pain 
and neuropathic pain. These anticonvulsants commonly cause 
cutaneous adverse drug reactions including fatal ones such 
as Stevens–Johnsons syndrome (SJS) and toxic epidermal 
necrolysis (TEN).127 These reactions are HLA-mediated 
immune reactions, and incidence of these adverse reactions 
is closely linked to specific HLA alleles.128–131
Clinical application of pain genomics
The CPIC has put forth dosing guidelines based on phar-
macogenetic variations for various drugs. There are dosing 
guidelines for codeine based on CYP2D6 genotype.132 
For PMs, it is suggested to consider other opioids such as 
morphine, NSAIDs, and acetaminophen because of no or 
suboptimal analgesic response to codeine therapy. Alterna-
tive analgesics need to be considered for UMs as codeine 
and tramadol are expected to cause significant and life-
threatening opioid adverse effects including respiratory 
depression and death.
Based on the CYP2C9 genotype, half the lowest recom-
mended doses of NSAIDs have to be started for PM, in order 
to avoid complications such as gastrointestinal bleeding.127 
Similarly, based on CYP2D6 genotype, doses of tricyclics 
used for chronic pain are to be reduced by 60% to avoid 
arrhythmias and myelosuppression in PMs.127
Knowledge on functional pain genomics and epigenetic 
modifications have opened new avenues for pain therapy. 
Epigenetics refers to the functional genetic changes, not 
directly involving changes in the nucleotide sequence of the 
gene but involving increase or decrease in the expression of 
gene, in response to environmental or developmental cues.94 
These changes are effected by dynamic, reversible chemical 
modification of the genome and are involved in differential 
gene expression throughout life. Some examples include 
DNA methylation regulated by DNA methyltransferases 
and histone acetylation regulated by histone deacetylases 
(HDAC). Poorly managed acute pain is known to increase 
pain sensitivity and the risk of chronic pain states, and epi-
genetic modifications are found to play an important role 
in this process.94 Drugs that target enzymes responsible for 
epigenetic variations are under development. In an animal 
pain model, DNA methyltransferase inhibitor, zebularine, 
has been found to reduce pain sensitivity.133,134 Similar stud-
ies have been done on animal models using HDAC inhibi-
tors as well.135 Valproic acid, an HDAC inhibitor, has been 
found to improve pain scores in humans with type II diabetes 
mellitus.136
Another potential development in the field of pain is the 
gene therapy, which involves the use of viral vectors, which 
are used to introduce a promoter sequence in the host cells, 
which drives the gene expression of interest. This allows 
a persistent expression of a protein-based endogenous 
analgesic agent at the site of action.94 This can significantly 
reduce the side effects of pharmacotherapy, but an inadequate 
expression of the transgene and immune elimination of the 
vector virus are the limitations.137 Nonviral insertion tech-
niques are being studied to overcome these problems.137 A 
study has been done in cancer patients, involving the PENK 
gene, encoding for preproenkephalin, which is the precursor 
of 6-met-enkephalin and 1-leu-enkephalin, which are endog-
enous delta-opioid receptor ligands. The highest virus groups 
have reported 50% lower pain on numerical rating scale.138
Conclusion
There is a lack of robust evidence to support a gender-specific 
analgesic management. Intragroup variations in pain percep-
tion at various stages of sexual development and a wide range 
of individual variations seem to be more clinically relevant 
than a broader gender categorization. Clinical application of 
genetic knowledge in pain management is still primitive due 
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to both existing knowledge gaps and the cost and access con-
straints. Urine drug testing is a commonly used tool for thera-
peutic monitoring. The qualitative tests have a high incidence 
of both false positives and false negatives. The quantitative 
assays are affected by a number of factors including the vol-
ume status and renal function of the patient. It poorly reflects 
the plasma drug level and the effect site concentration.94 The 
plasma drug level monitoring using mass spectrometry is a 
more reliable tool for therapeutic monitoring,94 but it does 
not give any idea about the pharmacodynamics of the drug. 
Genetic testing is still not widely adopted due to accessibil-
ity and questionable cost-effectiveness. Currently, genetic 
testing on oral, buccal mucosal samples has been clinically 
validated and also economically feasible; several SNPs are 
readily available for clinical use.139 With increasing number 
of studies on pain genetics and genome-wide association 
studies (GWAS) on pain underway, widespread genetic test-
ing is likely to become more practical and widely accessible 
in future. Personalized management algorithms for different 
pain models, taking into account the gender and multiple 
genetic variations, along with other contributing factors seem 
to be a reality in near future.
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